|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:fluvoxamine
|
|
gptkbp:approvedBy
|
1983
|
|
gptkbp:ATCCode
|
gptkb:N06AB08
|
|
gptkbp:availableOn
|
gptkb:Australia
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:brand
|
fluvoxamine maleate
|
|
gptkbp:CASNumber
|
61718-82-9
|
|
gptkbp:chemicalFormula
|
C15H21F3N2O2
|
|
gptkbp:contraindication
|
hypersensitivity to fluvoxamine
concomitant use with tizanidine
|
|
gptkbp:discoveredBy
|
gptkb:Solvay_Pharmaceuticals
|
|
gptkbp:drugClass
|
selective serotonin reuptake inhibitor
|
|
gptkbp:eliminationHalfLife
|
15-22 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:FDAApproved
|
yes
|
|
gptkbp:form
|
gptkb:tablet
extended-release tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Luvox
|
|
gptkbp:interactsWith
|
gptkb:theophylline
gptkb:warfarin
gptkb:MAO_inhibitors
gptkb:benzodiazepines
gptkb:clozapine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Abbott_Laboratories
|
|
gptkbp:marketedAs
|
gptkb:AbbVie
|
|
gptkbp:mechanismOfAction
|
inhibits serotonin reuptake
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children (OCD only)
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts (in young people)
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
insomnia
dry mouth
sexual dysfunction
somnolence
|
|
gptkbp:usedFor
|
gptkb:depression
gptkb:obsessive-compulsive_disorder
|
|
gptkbp:bfsParent
|
gptkb:fluvoxamine
|
|
gptkbp:bfsLayer
|
6
|